Seeking Alpha

Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>)...

Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. ">inappropriate parallels " between Jazz Pharmaceutical's (JAZZ -0.4%) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock.
Comments (8)
  • >Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%&l... Xyrem and Questcor's (QCOR) drug Acthar.

     

    Huh?
    28 Sep 2012, 06:23 PM Reply Like
  • Agreed, great proof reading. Not sure who they like....
    28 Sep 2012, 07:10 PM Reply Like
  • can someone clarify if they are referring to jazz or qcor regarding the 66$ price target? doesn't make sense.
    28 Sep 2012, 11:21 PM Reply Like
  • They misplaced the " mark before JAZZ, so the HTML font command was not properly parsed.

     

    Just ignore the text between " JAZZ... and ">, and the whole thing makes perfect sense.

     

    Obviously, then, the target of 66 is for JAZZ (fat chance with QCOR :( ). Oppenheimer has a lot of nerve talking about "inappropriate parallels" between JAZZ's drug and QCOR's, considering they were the ones who pumped QCOR into the 60s they day before the Citron bomb dropped.
    29 Sep 2012, 02:34 AM Reply Like
  • i don' t know, i saw they had oppenheimer had a 88 dollar price target for jazz. citron only orchestrates bear raids. they line up all the parties involved and pay them off. that guy is going to hell.
    29 Sep 2012, 08:21 AM Reply Like
  • yeah it makes sense now that i look at it, it is for jazz. but qcor reimburse issue is way over blown in my opinion.
    29 Sep 2012, 08:23 AM Reply Like
  • yeah but how bout all them class action lawsuits for securities fraud for misrepresentation of their product? that's going to be a big hit on earnings.
    2 Oct 2012, 01:39 PM Reply Like
  • Class action lawsuits first take years to go to trial and most do not and are settled out of court. Second, these types of lawsuits are difficult to prove unless there is just fragrant proof. There is some speculation that the FDA investigation was orchestrated by Mr Left from Citron who is well known short seller and has been convicted on securities crimes in the past. Time will tell. In the short term the only way for QCOR stock is up!!
    7 Oct 2012, 01:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)